tbuckley/cabot-search huggingface dataset:
Vocational and Counseling Service for Diabetics
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Silent Minorities
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prevalence and Economic Burden of Chronic Lymphocytic Leukemia (CLL) in the Era of Oral Targeted Therapies
Authors: Nitin Jain, Qiushi Chen, Turgay Ayer, Susan M. O'Brien, Michael Keating, William Wierda, Hagop M. Kantarjian, Chhatwal Jagpreet
Journal: Blood (2015)
Difficult/therapy-resistant asthma The need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies
Authors: None Ers
Journal: European Respiratory Journal (1999)

A Task Force supported by the European Respiratory Society was set up in 1997 in order to address the major issues relevant to difficult/therapy-resistant asthma.Although the group of patients involved is small in comparison to the high numbers of patients with asthma, these patients consume a significant proportion of medical resources in terms of both time and money [1].The major issues facing the Task Force were how to define "difficult asthma", how the patient with difficult asthma should be evaluated, the pathophysiological mechanisms underlying difficult asthma and the treatments available.The Task Force also concerned itself with defining the areas of research necessary to bring about a greater understanding of the causes of difficult asthma and novel treatments.The document resulting from this Task Force represents a consensus of different opinions, which will form the basis for further research. Formulating the definitionA large number of terms are used by clinicians when referring to asthmatic patients who have "difficult to treat" disease: difficult acute, difficult chronic, chronic severe, acute severe, therapy-resistant, difficult to control, corticosteroid-resistant or corticosteroid-dependent, symptomatic, life-threatening, and fatal.An encompassing inclusive rather than exclusive definition was sought and the use of the term "difficult/therapy-resistant asthma" was adopted to include all such cases of asthma of all age groups.Since wheezing disorders in preschool children are poorly characterized, this report specifically excludes children below the age of 5 yrs.Response to therapy is included in this concept and will have research implications.It was accepted that the definition needed to be inclusive, although losing some precision, but it was also recognized that its
STATE CARE OF THE INSANE IN NEW YORK.
Journal: JAMA (1892)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CORRECTION.
Journal: JAMA (1883)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MPTH-11. TARGETED NEXT-GENERATION SEQUENCING PANEL (GLIOSEQ) PROVIDES COMPREHENSIVE GENETIC PROFILING OF CENTRAL NERVOUS SYSTEM TUMORS
Authors: Marina Nikiforova, Abigail Wald, Melissa Melan, Somak Roy, Shan Zhong, Ronald Hamilton, Frank Lieberman, Jan Drappatz, Nduka Amankulor, Ian Pollack, Yuri Nikiforov, Craig Horbinski
Journal: Neuro-Oncology (2016)

Identification of genetic changes in CNS tumors can help improve patient management. We developed a next-generation sequencing (NGS) assay, which works even on very small biopsies, to detect various genetic alterations that are characteristic of adult and pediatric CNS tumors. This amplification-based targeted NGS assay (GlioSeq) analyzes 30 genes for single nucleotide variants (SNVs) and indels, 24 genes for copy number variations (CNVs), and 14 types of structural alterations in BRAF, EGFR, and FGFR3 genes in a single workflow. GlioSeq performance was evaluated in 54 adult and pediatric CNS tumors and results were compared to FISH, Sanger sequencing and RT-PCR. GlioSeq correctly identified 71/71 (100%) genetic alterations detected by conventional techniques, including 56 SNVs/indels, 9 CNVs, 3 EGFRvIII, and 3 KIAA1549-BRAF fusions. Only 20 ng of DNA and 10 ng of RNA was required for successful sequencing of 100% frozen and 96% formalin-fixed, paraffin-embedded tissue specimens. The assay sensitivity was 3-5% of mutant alleles for SNVs and 1-5% for gene fusions. The most commonly detected alterations were IDH1, TP53, TERT, ATRX. CDKN2A, and PTEN in high-grade gliomas, followed by BRAF fusions in low-grade and H3F3A mutations in pediatric gliomas. GlioSeq accurately and sensitively detects a wide range of genetic alterations in a single workflow, and often identifies unexpected alterations that greatly impact the care of brain tumor patients. Specific examples of such cases will be presented, including how patient care was improved with the information provided by GlioSeq.
Klinische Wochenschrift, Berlin
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Third Annual European Organization for Cooperation in Cancer Prevention Studies (ECP) Symposium
Journal: JNCI Journal of the National Cancer Institute (1985)

Journal Article Third Annual European Organization for Cooperation in Cancer Prevention Studies (ECP) Symposium Get access JNCI: Journal of the National Cancer Institute, Volume 74, Issue 2, February 1985, Page 542, https://doi.org/10.1093/jnci/74.2.542-b Published: 01 February 1985
The physician and hypertension
Authors: M. D. Cheitlin
Journal: JAMA (1974)

HYPERTENSION is a disease affecting 23 million Americans—a public health menace of great magnitude. We have the means to control hypertension in the great majority of patients, and there is convincing evidence that such control will reduce morbidity and mortality. With such knowledge and capability, why do we still have 50% of hypertensives unaware that they have the disease, while many others are not on adequate treatment (or any treatment).<sup>1</sup>Where lies the fault? With the patient, the doctor, or both? The National Heart and Lung Institute (NHLI) has undertaken to coordinate a National Program of Information and Education to educate the public and alert the medical profession to the problem of "hidden" hypertension. As part of this program, the NHLI contracted with Louis Harris and Associates to conduct a survey of current public awareness and knowledge of high blood pressure. The survey was carefully designed and carried out
"TREATMENT OF PYLOROSPASM IN INFANTS"
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 1175: Critical Role of Bone Marrow ASC (Apoptosis-associated Speck-like Protein Containing a CARD) in Neointimal Formation After Vascular Injury in Mice
Authors: Noriyuki Yajima, Masafumi Takahashi, Yuji Shiba, Hirohiko Ise, Yasuko Takahashi, Junji Sagara, Shunichiro Taniguchi, Uichi Ikeda
Journal: Circulation (2007)

Background: ASC is an adaptor protein that forms inflammasome complex and regulates caspase-1-dependent interleukin (IL)-1β and IL-18 generation; however, the role of ASC in the pathophysiology of cardiovascular diseases remains undefined. Here, we investigated the contribution of ASC to neointimal formation after vascular injury in ASC-deficient (ASC −/− ) mice. Methods and Results: Wire-mediated vascular injury was produced in the femoral artery of ASC −/− and wild-type (WT: C57BL/6) mice. Immunohistochemical analysis revealed that ASC was markedly expressed in the infiltrated macrophages in the neointima. Histological analysis revealed that neointimal formation was significantly reduced in ASC −/− mice as compared to that in the WT mice (I/M ratio, p = 0.007). IL-1β and IL-18 were clearly expressed in the neointimal lesion of the WT mice but showed decreased expression in the lesion of ASC −/− mice. However, TUNEL staining showed no significant difference in apoptotic cells of the media between these mice. Further, no significant differences were observed in early reendothelialization (CD31) and the number of macrophages (F4/80) and smooth muscle cells (SMCs: αSMA) per unit of the neointima. Flow cytometry analysis also showed no difference in the number of peripheral CD34 + /Flk-1 + cells (EPCs) after injury. To determine the contribution of bone marrow cells, we developed 3 types of bone marrow transplantation (BMT Wild+Wild , BMT Wild+ASC−/− , and BMT ASC−/− → Wild ) mice. The neointimal formation in BMT ASC−/−+Wild mice mice was remarkably reduced as compared to that in BMT Wild+Wild (I/M ratio, p = 0.0003) and BMT Wild+ASC−/− mice (p = 0.015), indicating that bone marrow ASC is critical for neointimal formation. In vitro experiments showed that the lipopolysaccharide-induced production of inflammatory cytokines such as IL-1β, IL-6, MCP-1, and IFN-γ, but not TNF-α, in ASC −/− bone marrow cells was significantly decreased. Further, serum-stimulated proliferation activity and MAP kinase (ERK1/2 and p38) activation of ASC −/− SMCs were not impaired. Conclusions: These findings suggest that bone marrow-derived ASC is critical for the neointimal formation after vascular injury and identify ASC as a novel therapeutic target for cardiovascular diseases.
Ultrasound diagnosis of Baker cyst
Authors: J. C. Rudikoff
Journal: JAMA (1976)

BAKER cysts may dissect or rupture into the calf, producing a syndrome mimicking thrombophlebitis. Ultrasound B scan of the calf can demonstrate the cystic nature of this lesion and lead to correct diagnosis and treatment. Routine double-contrast arthrography was not done in our patient because of previous allergy to contrast medium. Ultrasound B scan is correlated with air arthrography and surgery. <h3>Report of a Case</h3> A 69-year-old asthmatic man was admitted to University Hospital on Nov 17, 1974, with the chief complaint of progressive right calf pain and swelling of six weeks' duration. In the previous year, he had had aching pain and recurrent swelling of the right knee. He denied a history of trauma or twisting injury to the knee but admitted to occasional painful clicking when he crossed his legs. Five weeks prior to admission, the knee joint was tapped, and a steroid preparation was injected, with temporary
THE TREATMENT OF EPILEPSY WITH OPIUM AND BROMID.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Activities
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CREBBP Loss Cooperates with BCL2 Over-Expression to Promote Lymphoma in Mice
Authors: García-Ramírez Idoia, Shashank Shrishrimal, Ines Gonzalez-Herrero, Alberto Martín-Lorenzo, Guillermo rodriguez-Hernandez, Romain Duval, Dalia Moore, Lucia Ruiz-Roca, Oscar Blanco, Diego Alonso-Lopez, Javier de Las Rivas, David Klinkibiel, Martin Bast, Timothy C. Greiner, Julie M Vose, Matthew Lunning, Fernando Rodrigues-Lima, Rafael Jiménez, Francisco Garcia-criado, Maria garcia Cenador, Paul Brindle, Carolina vicente-Duenas, Isidro Sánchez-García, Michael R Green
Journal: Blood (2016)
State and National Vaccination Coverage Levels Among Children Aged 19-35 Months — United States, April-December 1994
Journal: JAMA (1995)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 3457: Flubendazole targets STAT3 signaling and distant metasis in triple-negative breast cancer
Authors: Eunhye Oh, Yoon-Jae Kim, Seojin Jang, Tae-Min Cho, Soeun Park, Jung Min Park, Minsu Park, Ji Young Kim, Jae Hong Seo
Journal: Cancer Research (2019)

Abstract Triple-negative breast cancers (TNBC) with higher cancer stem-like populations are reported to exhibit a more aggressive metastatic phenotype. In the present study, we investigated the effects of flubendazole, a candidate drug for repurposing and its novel mechanism of action with a focus on targeting STAT3 signaling and breast cancer stem-like traits in TNBC. The effect of FLU on TNBC cell lines in vitro was evaluated in terms of cell viability, breast cancer stem cells (BCSC)-like properties and expression of STAT3 signaling-related factors. An orthotopic injection model with BCSC-enriched population was used to examine the effect of flubendazole on tumor growth and metastasis in vivo. Our results showed that the BCSC-enriched populations harbored a higher Aldefluor-positive population and markedly elevated levels of CD49f and ALDH1A1 as well as higher STAT3 activation in vitro. Flubendazole attenuated STAT3 activation, as demonstrated by a significant reduction in phospho-STAT3 levels as well as subsequent downregulation of its downstream effector cyclin D1. Sphere-forming ability was significantly suppressed following two pharmacological STAT3 inhibitor, LLL12 or S3I-201 challenge. Treatment with interleukin-6 (IL-6) was observed to significantly increase the number and volume of mammospheres, while flubendazole abolished this effect. Bioluminescence in vivo imaging (BLI) revealed that the BCSC-enriched populations exhibited enhanced metastasis with higher STAT3 activation, while flubendazole administration inhibited tumor growth and lung and liver metastasis, coinciding with decreased MMP-2 and MMP-9 levels in circulating blood. To our knowledge, these findings are the first to report that flubendazole reduces BCSC-enriched tumor burden and metastasis via STAT3 inactivation, implying that flubendazole treatment may have application in addressing metastasis. Citation Format: Eunhye Oh, Yoon-Jae Kim, Seojin Jang, Tae-Min Cho, Soeun Park, Jung Min Park, Minsu Park, Ji Young Kim, Jae Hong Seo. Flubendazole targets STAT3 signaling and distant metasis in triple-negative breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3457.